Biotron Ltd (BITOC)
- 0.001
- 0.0000.00%
Biotron Ltd (BITOC) News
Biotron Advances Hepatitis B Candidate BIT-HBV001 Toward Human Trials After Strong Preclinical Data
Biotron Lists Additional Ordinary Shares Following Option Conversions
Biotron Secures R&D Tax Rebate to Support Antiviral Drug Development
Biotron Advances SedRx Anaesthetic Program and Expands Hepatitis Portfolio
Biotron Announces Leadership Transition as Long-Term Chairman Retires
Biotron Strengthens Board With Appointment of Veteran Life Sciences Executive
Biotron Cautions Investors on Risks in Forward-Looking Statements
Biotron Expands Hepatitis B Drug Potential and Advances Sedarex Integration
Biotron Posts Wider Half-Year Loss Amid Zero Revenue and Raised Asset Backing
Biotron Director Robert Thomas Retires After 14 Years on Board
Biotron Completes Fully Subscribed Rights Issue to Fund Diversified Portfolio
Biotron Expands With Sedarex Acquisition and Reports Strong Preclinical HBV Drug Data
Biotron Directors Lift Holdings Through Rights Issue Participation
Biotron Seeks ASX Quotation for 181.7 Million New Options
Biotron Appoints Veteran Life Sciences Executive Paul Kasian as Non-Executive Director
Biotron Shares Reinstated to Quotation on ASX
Biotron Issues 181.7 Million Unquoted Options Expiring in 2027
Biotron Discloses Top 20 Holders and Distribution of Newly Listed Options
Biotron Raises $645,861 via Rights Issue to Advance Hepatitis B Program
Biotron Limited's BITO Securities Suspended by ASX